Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, University of Athens Medical School, 'Aghia Sophia' Children's Hospital, Athens 11527, Greece.
Sci Signal. 2012 Oct 2;5(244):pt5. doi: 10.1126/scisignal.2003337.
Primary generalized glucocorticoid resistance (PGGR or Chrousos syndrome) and primary generalized glucocorticoid hypersensitivity (PGGH) are rare genetic disorders characterized by generalized, partial target-tissue insensitivity or hypersensitivity to glucocorticoids, respectively, while also causing compensatory alterations in the activity of the hypothalamic-pituitary-adrenal axis. The molecular basis of Chrousos syndrome and PGGH has been ascribed to mutations in the gene encoding the human glucocorticoid receptor (hGR), which impair glucocorticoid signal transduction and alter tissue sensitivity to glucocorticoids. Alterations in hGR action may have important implications for many critical biological processes, such as the behavioral and physiologic responses to stress, immune responses, growth, and reproduction. This Presentation summarizes the pathophysiology, clinical manifestations, and molecular mechanisms of the PGGR and PGGH states.
原发性全身性糖皮质激素抵抗(PGGR 或 Chrousos 综合征)和原发性全身性糖皮质激素超敏(PGGH)是罕见的遗传疾病,其特征分别为全身性、部分靶组织对糖皮质激素的不敏感或超敏,同时也导致下丘脑-垂体-肾上腺轴的代偿性改变。Chrousos 综合征和 PGGH 的分子基础归因于编码人糖皮质激素受体(hGR)的基因突变,该突变损害糖皮质激素信号转导并改变组织对糖皮质激素的敏感性。hGR 作用的改变可能对许多关键的生物学过程具有重要意义,如对压力的行为和生理反应、免疫反应、生长和繁殖。本演讲总结了 PGGR 和 PGGH 状态的病理生理学、临床表现和分子机制。